Abstract
Cholestatic jaundice caused by imidazole derivates is a rare complication of antithyroid therapy. Only 20 such cases have been reported in the literature since the introduction of methimazole in 1949 and of carbimazole in 1953. We present a further case of methimazole-induced cholestatic liver injury, mimicking sclerosing cholangitis, where the etiology has been proven by a clear chronological relationship and the lack of other causative factors.
Zusammenfassung
Als seltene Nebenwirkung einer Therapie der Hyperthyreose mit Imidazolabkömmlingen wurde das Auftreten einer mechanischen Cholestase beschrieben. 20 derartige Fälle wurden seit der Einführung von Methimazol 1949 und von Carbimazol 1953 publiziert. Wir berichten über den weiteren Fall einer mechanischen Cholestase unter Methimazoltherapie, die mit dem radiologischen Bild einer primär sklerosierenden Cholangitis einherging.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Stanley MM, Astwood EB (1949)1-Methyl-mercaptoimidazole: an antithyroid compound highly active in man. Endocrinology 44:588–589
BarthelsEC (1953) Clinical experience with a new antithyroid drug: 2-carbebethoxylthio-l-methylglyoxaline. J Clin Endocrin 12:1305–1311
Becker CE, Gordon P, Robbins J (1968) Hepatitis from methimazole during adrenal steroid therapy for malignant exophthalmus. JAMA 206:1787–1789
Efstratiadis N, Holzberg R, Schmidt W, Teuber G, Wildhirt E (1982) Toxische cholestatische Hepatose durch Thiamazol und Carbimazol. Dtsch Med Wochenschr 107:1531–1533
Fischer MG, Nayer HR, Miller A (1973) Methimazole-induced jaundice. JAMA 223:1028–1029
Martinez-Lopez JI, Greenberg SE, Kling RR (1962) Drug-induced hepatic injury during methimazole therapy. Gastroenterology 43: 84–87
Rosenbaum H, Reveno WS (1953) Agranulocytosis and toxic hepatitis from methimazole. JAMA 152:27
Schmidt G, Börsch G, Müller KM, Wegener M (1986) Methimazole-associated cholestatic liver injury: case report and brief literature review. Hepatogastroenterology 33:244–246
Shipp JC (1955) Jaundice during methimazole (“tapazole”) administration. Ann Intern Med 42:701–706
Specht NW, Boehme EJ (1952) Death due to agranulocytosis induced by methimazole therapy. JAMA 149:1010–1011
Tennenbaum JI, Dreskin OH (1962) Toxic hepatitis during treatment with methimazole (tapazole). Ohio State Med J 58:306–307
Arab DM, Malatjalian DA, Rittmaster RS (1995) Severe cholestatic jaundice in uncomplicated hyperthyroidism treated with methimazole. J Clin Endocrinol Metab 80:1083–1085
Ayensa C, De Otazu DR, Cia JM (1986) Carbimazole-induced cholestatic hepatitis. Arch Intern Med 146:1455
Blom H, Stolk J, Schreuder HB, Von Blomberg-van der Flier M (1985) A case of carbimazole-induced intrahepatic cholestasis: an immune-mediated reaction? Arch Intern Med 145:1513–1515
Lunzer M, Huang SN, Ginsburg J, Ahmed M, Sherlock S (1975) Jaundice due to carbimazole. Gut 16:913–917
Prost G, Dechavanne M, Levenq P, Tolot F (1973) Ictere cholostatique du an carbimazole. Nouv Press Med 2:2479
Kuschinsky G, Lullman H (1981) Endokirne Drüsen. In: Lehrbuch der Pharmakologie. Thieme, Stuttgart, pp 265–300
Chen LY, Goldberg HI (1984) Sclerosing cholangitis: broad spectrum of radiographic features. Gastrointest Radiol 9:39–47
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Schwab, G.P., Wetscher, G.J., Vogl, W. et al. Methimazole-induced cholestatic liver injury, mimicking sclerosing cholangitis. Langenbecks Arch Chiv 381, 225–227 (1996). https://doi.org/10.1007/BF00571690
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF00571690